Last $0.14 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 02/17/15 All times are local (Market data is delayed by at least 15 minutes).

prana biotechnology ltd (PRNAF) Snapshot

Open
$0.14
Previous Close
$0.14
Day High
$0.14
Day Low
$0.14
52 Week High
02/28/14 - $1.26
52 Week Low
02/17/15 - $0.14
Market Cap
76.4M
Average Volume 10 Days
1.0K
EPS TTM
--
Shares Outstanding
527.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRANA BIOTECHNOLOGY LTD (PRNAF)

Related News

No related news articles were found.

prana biotechnology ltd (PRNAF) Related Businessweek News

View More BusinessWeek News

prana biotechnology ltd (PRNAF) Details

Prana Biotechnology Limited develops therapies for the treatment of neurodegenerative diseases in Australia. The company focuses on the Alzheimer‘s and Huntington‘s diseases, as well as other age-related degeneration disorders. Its lead drug candidate includes PBT2 for the treatment of Alzheimer’s and Huntington’s diseases. The company’s other development products that are in pre-clinical trials comprise PBT434 that is used for the treatment of Parkinson’s disease and other movement disorders; and PBT519, which is used to treat brain cancer. It also has a library of approximately 1000 metal protein attenuating compounds, which support new therapies for the treatment of neurodegenerative disease and other highly prevalent conditions. The company was founded in 1997 and is based in Parkville, Australia.

12 Employees
Last Reported Date: 11/3/14
Founded in 1997

prana biotechnology ltd (PRNAF) Top Compensated Officers

Co-Founder, Executive Chairman and Chief Exec...
Total Annual Compensation: A$444.4K
Chief Operating Officer
Total Annual Compensation: A$324.8K
Company Secretary
Total Annual Compensation: A$50.0K
Compensation as of Fiscal Year 2014.

prana biotechnology ltd (PRNAF) Key Developments

Prana Biotechnology Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Prana Biotechnology Limited reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported loss after income tax of AUD 1,252,695 compared to AUD 7,928,392 for the same period a year ago. Revenue from ordinary activities was AUD 92,581 compared to AUD 189,588 a year ago. Loss before income tax expense was AUD 1,252,695 compared to AUD 7,928,392 a year ago. Basic and diluted loss per share was 0.26 cents compared to 1.97 cents a year ago. Net operating cash flows were AUD 8,411,407 compared to AUD 7,435,475 a year ago. Payment for purchases of plant and equipment was AUD 24,942 compared to AUD 12,718 a year ago. The loss has decreased compared to previous year due to a gain on foreign exchange, an increase in other income related to the R&D Tax Concession and a decrease in expenditure on research and development.

Prana Biotechnology Limited - Shareholder/Analyst Call

Annual General Meeting

Prana Biotechnology Limited Announces Executive Changes

Prana Biotechnology Limited announced the appointment of Ms. Kathryn Andrews as Chief Financial Officer and Mr. Phillip Hains as Company Secretary. Ms Andrews is a Certified Practicing Accountant and has over 25 years' experience in accounting, commercial management and consulting in various roles. For the past two years Ms. Andrews has held a senor role with The CFO Solution. As principal of The CFO Solution since 1996, Mr. Hains is the Company Secretary for a number of listed companies in the life sciences sector. The appointment follows the resignation of Mr. Richard (Rick) Revelins from the role of CFO and Company Secretary to pursue other commercial interests in the USA. The changes are effective immediately.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRNAF:US $0.14 USD 0.00

PRNAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRNAF.
View Industry Companies
 

Industry Analysis

PRNAF

Industry Average

Valuation PRNAF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.5x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRANA BIOTECHNOLOGY LTD, please visit www.pranabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.